You are in: eMedicine Specialties > Dermatology > REACTIVE AND INFLAMMATORY DERMATOSES Pruritic Urticarial Papules and Plaques of PregnancyArticle Last Updated: Mar 25, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Joseph C Pierson, MD, Consulting Staff, Department of Dermatology, Keller Army Community Hospital Joseph C Pierson is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology Coauthor(s): Christine C Tam, MD Editors: Abdul-Ghani Kibbi, MD, Chairman and Professor, Department of Dermatology, American University of Beirut Medical Center, Lebanon; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Edward F Chan, MD, Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System Author and Editor Disclosure Synonyms and related keywords: polymorphic eruption of pregnancy, PEP, toxemic erythema of pregnancy, toxemic rash of pregnancy, late-onset prurigo of pregnancy, PUPPP, benign dermatosis, pregnancy-related dermatoses, erythematous urticarial papules, intensely pruritic papules INTRODUCTIONBackgroundPruritic urticarial papules and plaques of pregnancy (PUPPP) is a benign dermatosis that usually arises late in the third trimester of a first pregnancy. The entity previously had been reported as toxemic rash of pregnancy, toxemic erythema of pregnancy, and late-onset prurigo of pregnancy. The term polymorphic eruption of pregnancy (PEP) is used extensively in Great Britain, while PUPPP typically is used in the United States. Following atopic eruption of pregnancy, which occurs earlier in gestation, PUPPP is the second most common dermatoses of pregnancy.1 FrequencyInternationalPUPPP occurs in 1 out of 160-240 initial pregnancies. Mortality/MorbidityNo mortality is associated with PUPPP. The mere appearance of an unusual skin eruption in pregnancy can provoke anxiety, but the pruritus is the most distressing feature. The latter weeks of pregnancy can be associated with many physical symptoms, and the severe itching of PUPPP may further debilitate and aggravate sleep loss in the weeks prior to delivery. No known systemic complications exist for affected females, and fetal mortality or morbidity do not increase. RacePUPPP may be less common in blacks. SexPUPPP occurs in females only. AgePUPPP occurs during childbearing years because it is a dermatosis related to pregnancy. CLINICALHistoryPUPPP typically begins with intensely pruritic papules arising within striae distensae late in the third trimester of a first pregnancy. Of all cases, 73% are seen in primigravidae pregnancies.1 Additionally, 11.7 % of affected females are multiple-gestation pregnancies.2 As many as 15% of PUPPP cases arise in the immediate postpartum period.1 In a few days, the eruption spreads to the trunk and extremities. Patients present for a diagnosis of their unusual skin eruption and seek relief from the intense itching. PhysicalClassic PUPPP reveals papules within prominent striae distensae (see Media Files 1-2). Erythematous urticarial papules and plaques of the trunk and extremities also are observed, although the periumbilical area is spared. Small vesicles often are noted, but larger bullae do not occur and would suggest the more rare herpes gestationis. Less commonly, target lesions and annular and polycyclic wheals may be present. PUPPP usually does not affect the face, palms, or soles. Although the eruption is intensely pruritic, excoriations rarely are found. CausesThe cause and pathogenesis of PUPPP are not known. A meta-analysis reveals 11.7% of patients with PUPPP are multiple gestation pregnancies.2 Within that group, a higher PUPPP risk for triplet (14%) over twin (2.9%) pregnancies has been published,3 suggesting a relationship between skin distension and the development of PUPPP. Most studies reveal increased maternal weight gain in patients with PUPPP when compared with normal pregnancies, further supporting the role of increased skin distension.4 DIFFERENTIALSContact Dermatitis, Allergic Contact Dermatitis, Irritant Drug Eruptions Erythema Multiforme Insect Bites Scabies Seabather's Eruption Urticaria, Acute Urticaria, Chronic
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Fluocinonide (Fluonex, Lidex) |
|---|---|
| Description | Class II topical steroid. High-potency, topical, corticosteroid that inhibits cell proliferation; is immunosuppressive and anti-inflammatory. |
| Adult Dose | Apply sparingly bid/qid as severity warrants |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; herpes simplex infection; fungal, viral, or tubercular skin lesions |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | May cause adverse systemic effects if used over large areas, denuded areas, on occlusive dressings, or during prolonged treatment periods; do not apply to areola in breastfeeding; use weaker topical steroid (hydrocortisone) for facial or intertriginous involvement |
| Drug Name | Prednisone (Deltasone) |
|---|---|
| Description | May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity. |
| Adult Dose | 0.5-1 mg/kg/d PO |
| Pediatric Dose | 1-2 mg/kg PO qd or divided bid/qid; taper over 2 wk as symptoms resolve |
| Contraindications | Documented hypersensitivity; viral infection, peptic ulcer disease, hepatic dysfunction, connective tissue infections, and fungal or tubercular skin infections; severe gestational diabetes or hypertension |
| Interactions | Coadministration with estrogens may decrease prednisone clearance; when used with digoxin, digitalis toxicity secondary to hypokalemia may increase; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use |
Sedative effect may improve sleep.
| Drug Name | Diphenhydramine (Benadryl, Belix) |
|---|---|
| Description | For symptomatic relief of pruritus caused by release of histamine in inflammatory reactions. |
| Adult Dose | 25-50 mg PO qhs |
| Pediatric Dose | 12.5-25 mg PO tid/qid, or 5 mg/kg/d, or 150 mg/m2/d divided tid/qid; not to exceed 300 mg/d |
| Contraindications | Documented hypersensitivity; MAOIs |
| Interactions | Potentiates effect of CNS depressants; due to alcohol content, do not give syrup dosage form to patient taking medications that can cause disulfiramlike reactions |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Drowsiness; neonatal sedation; may exacerbate angle-closure glaucoma, hyperthyroidism, peptic ulcer, and urinary tract obstruction |
| Media file 1: Courtesy of Jeffrey P. Callen, MD of Louisville, Kentucky. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Courtesy of Jeffrey P. Callen, MD of Louisville, Kentucky. | |
![]() | View Full Size Image | Media type: Photo |
Pruritic Urticarial Papules and Plaques of Pregnancy excerpt
Article Last Updated: Mar 25, 2008